Extract of Magnoliae Flos inhibits ovariectomy-induced osteoporosis by blocking osteoclastogenesis and reducing osteoclast-mediated bone resorption

Fitoterapia

Volumn 83, Issue 8, 2012, Pages 1523-1531

  Jun, Ah Young ^a   Kim, Hyun Jeong ^a   Park, Kwang Kyun ^a,b   Son, Kun Ho ^c   Lee, Dong Hwa ^c   Woo, Mi Hee ^d   Kim, Yeong Shik ^e   Lee, Sang Kook ^e   Chung, Won Yoon ^a,b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Dentistry   (South Korea)

^c Andong National University   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Bone resorption; Cathepsin K; Magnoliae Flos; Matrix metalloproteinases; Osteoclast differentiation; Ovariectomy induced osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CALCIUM; CATHEPSIN K; MAGNOLIAE FLOS EXTRACT; MATRIX METALLOPROTEINASE; OSTEOCALCIN; PLANT EXTRACT; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; MACROPHAGE; MAGNOLIAE FLOS; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRABECULAR BONE;

ANIMALS; BONE RESORPTION; FEMALE; MAGNOLIACEAE; MALE; MICE; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; PLANT EXTRACTS; RANDOM ALLOCATION;

FLOS; MURINAE; MUS;

EID: 84870773944     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2012.08.020     Document Type: Article

References (26)

1. N. Harvey, E. Dennison, and C. Cooper Osteoporosis: impact on health and economics Nat Rev Rheumatol 6 2010 99 105
2. G.R. Mundy Osteoporosis and inflammation Nutr Rev 65 12 pt 2 2007 S147 S151
3. L.G. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508 1514
4. S. Davison, and S.R. Davis Hormone replacement therapy: current controversies Clin Endocrinol 58 2003 249 261
5. J.J. Body, P. Bergmann, S. Boonen, J.P. Devogelaer, E. Gielen, and S. Goemaere Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications Osteoporos Int Suppl. 1 2012 S1 S23
6. R.B. Kimble, A.B. Matayoshi, J.L. Vannice, V.T. Kung, C. Williams, and R. Pacifici Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period Endocrinology 136 1995 3054 3061
7. M.A. Brown Antibody treatments of inflammatory arthritis Curr Med Chem 12 2005 2943 2946
8. Y. Shen, E.C.K. Pang, C.C.L. Xue, Z.Z. Zhao, J.G. Lin, and C.G. Li Inhibitions of mast cell-derived histamine release by different Flos Magnoliae species in rat peritoneal mast cells Phytomedicine 15 2008 808 814
9. Y. Shen, C.G. Li, S.F. Zhou, E.C. Pang, D.F. Story, and C.C. Xue Chemistry and bioactivity of Flos Magnoliae, a Chinese herb for rhinitis and sinusitis Curr Med Chem 15 16 2008 1616 1627
10. J.A. Baek, Y.D. Lee, C.B. Lee, H.K. Go, J.P. Kim, and J.J. Seo Extracts of Magnoliae Flos inhibit inducible nitric oxide synthase via ERK in human respiratory epithelial cells Nitric Oxide 20 2009 122 128
11. S. Kobayashi, H. Kobayashi, H. Matsuno, I. Kimura, and M. Kimura Inhibitory effects of anti-rheumatic drugs containing magnosalin, a compound from â€̃Shin-i’ (Flos magnoliae), on the proliferation of synovial cells in rheumatoid arthritis models Immunopharmacology 39 1998 139 147
12. R.A. Dixon Phytoestrogens Annu Rev Plant Biol 55 2004 225 261
13. H. Lim, K.H. Son, K.H. Bae, T.M. Hung, Y.S. Kim, and H.P. Kim 5-Lipoxygenase-inhibitory constituents from Schizandra fructus and Magnolia flos Phytother Res 23 2009 1489 1492
14. National Osteoporosis Foundation Fast facts 2010 http://www.nof.org/node/ 40
15. J. Banu, E. Varela, and G. Fernandes Altenative therapies for the prevention and treatment of osteoporosis Nutr Rev 70 2012 22 40
16. D.N. Kalu The ovariectomized rat model of postmenopausal bone loss Bone Miner 15 1991 175 191
17. L.G. Raisz Pathogenesis of osteoporosis: concepts, conflicts, and prospects J Clin Invest 115 2005 3318 3325
18. R. Baron, and E. Hesse Update on bone anabolic in osteoporosis treatment: rationale, current status, and perspectives J Clin Endocrinol Metab 97 2012 311 325
19. T.D. Rachner, S. Khosla, and L.C. Hofbauer Osteoporosis: now and the future Lancet 377 2011 1276 1287
20. S. Boonen, E. Rosenberg, F. Claessens, D. Vanderschueren, and S. Papapoulos Inhibition of cathepsin K for treatment of osteoporosis Curr Osteoporos Rep 10 2012 73 79
21. H.K. Vaananen, E.K. Karhukorpi, K. Sundquist, B. Wallmark, I. Roininen, and T. Hentunen Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts J Cell Biol 111 1990 1305 1311
22. D.J. Hadjidakis, and I.I. Androulakis Androulakis II. Bone remodeling Ann N Y Acad Sci 1092 2006 385 396
23. T.L. Andersen, M. del Carmen Ovejero, T. Kirkegaard, T. Lenhard, N.T. Foged, and J.M. Delaissé A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells Bone 35 2004 1107 1119
24. A.G. Costa, N.E. Cusano, B.C. Silva, S. Cremers, and J.P. Bilezikian Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis Nat Rev Rheumatol 7 2011 447 456
25. F. Lecaille, D. Bromme, and G. Lalmanach Biochemical properties and regulation of cathepsin K activity Biochimie 90 2008 208 226
26. Z. Fang, C.M. Shen, D.C. Moon, K.H. Son, J.K. Son, and M.H. Woo Quantitative and pattern recognition analyses for the quality evaluation of Magnoliae Flos by HPLC Bull Korean Chem Soc 31 2010 3371 3381